India’s Cadila Takes Saroglitazar Into NASH
This article was originally published in PharmAsia News
Executive Summary
The Indian drug maker Zydus Cadila is working to treat NASH, the serious fatty liver disease, with its established diabetes dyslipidemia compound saroglitazar, which gained approval in India in 2013.